A Concise Analytical Profile of Efavirenz: Analytical Methodologies

References

• Mayer, K. H.; Venkatesh, K. K. Antiretroviral Therapy as HIV Prevention: Status and Prospects. Am J Public Health. 2010, 100, 1867–1876. DOI: 10.2105/AJPH.2009.184796.
   PubMed Web of Science ®Google Scholar
• Arts, E. J.; Hazuda, D. J. HIV-1 Antiretroviral Drug Therapy. Cold Spring Harb. Perspect Med. 2012, 2, a007161. DOI: 10.1101/cshperspect.a007161.
   PubMed Web of Science ®Google Scholar
• Pau, A. K.; George, J. M. Antiretroviral Therapy: Current Drugs. Infect. Dis. Clin. North Am. 2014, 28, 371–402. DOI: 10.1016/j.idc.2014.06.001.
   PubMed Web of Science ®Google Scholar
• Rakhmanina, N. Y.; van den Anker, J. N. Efavirenz in the Therapy of HIV Infection. Expert Opin. Drug Metab. Toxicol. 2010, 6, 95–103. DOI: 10.1517/17425250903483207.
   PubMed Web of Science ®Google Scholar
• Pierce, M. E.; Parsons, R. L.; Radesca, L. A.; Lo, Y. S.; Silverman, S.; Moore, J. R.; Islam, Q.; Choudhury, A.; Fortunak, J. M. D.; Nguyen, D.; et al. Practical Asymmetric Synthesis of Efavirenz (DMP 266), an HIV-1 Reverse Transcriptase Inhibitor. J. Org. Chem. 1998, 63, 8536–8543. DOI: 10.1021/jo981170I.
   Web of Science ®Google Scholar
• De Clercq, E. Antiviral Drugs: current State of the Art. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 2001, 22, 73–89. DOI: 10.1016/S1386-6532(01)00167-6.
   Web of Science ®Google Scholar
• Maggiolo, F. Efavirenz: A Decade of Clinical Experience in the Treatment of HIV. J. Antimicrob. Chemother. 2009, 64, 910–928. DOI: 10.1093/jac/dkp334.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 64139, Efavirenz. https://pubchem.ncbi.nlm.nih.gov/compound/Efavirenz. (accessed Dec 22, 2020).
   Google Scholar
• United State Food and Drug Administration. FDA-Approved Drugs. http://www.accessdata.fda.gov/drugsatfdadocs/label/2010/020972s036lbl. (accessed Dec 22, 2020).
   Google Scholar
• Kasim, N. A.; Whitehouse, M.; Ramachandran, C.; Bermejo, M.; Lennernäs, H.; Hussain, A. S.; Junginger, H. E.; Stavchansky, S. A.; Midha, K. K.; Shah, V. P.; et al. Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Mol. Pharmaceutics 2004, 1, 85–96. DOI: 10.1021/mp034006h.
   PubMed Web of Science ®Google Scholar
• Kamble, R. N.; Mehta, P. P.; Kumar, A. Efavirenz Self-Nano-Emulsifying Drug Delivery System: In Vitro and in Vivo Evaluation. AAPS PharmSciTech 2016, 17, 1240–1247. DOI: 10.1208/s12249-015-0446-2.
   PubMed Web of Science ®Google Scholar
• Rabel, S. R.; Maurin, M. B.; Rowe, S. M.; Hussain, M. Determination of the pKa and pH-Solubility Behavior of an Ionizable Cyclic Carbamate, (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4- (trifluoromethyl)-2H-3,1-benzoxazin-2-one (DMP 266). Pharm. Dev. Technol. 1996, 1, 91–95. DOI: 10.3109/10837459609031422.
   PubMedGoogle Scholar
• Gao, J. Z. H.; Hussain, M. A.; Motheram, R.; Gray, D. A. B.; Benedek, I. H.; Fiske, W. D.; Doll, W. J.; Sandefer, E.; Page, R. C.; Digenis, G. A. Investigation of Human Pharmacoscintigraphic Behavior of Two Tablets and a Capsule Formulation of a High Dose, Poorly Water Soluble/Highly Permeable Drug (Efavirenz). J. Pharm. Sci. 2007, 96, 2970–2977. DOI: 10.1002/jps.20962.
   PubMed Web of Science ®Google Scholar
• Gupta, E.; Barends, D. M.; Yamashita, E.; Lentz, K. A.; Harmsze, A. M.; Shah, V. P.; Dressman, J. B.; Lipper, R. A. Review of Global Regulations concerning Biowaivers for Immediate Release Solid Oral Dosage Forms. Eur. J. Pharm. Sci. 2006, 29, 315– 324. DOI: 10.1016/j.ejps.2006.05.001.
   PubMed Web of Science ®Google Scholar
• U. S. Food and Drug Administration. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on Biopharmaceutics Classification System Guidenance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/waiver-vivo-bioavailability-and-bioequivalence-studies-immediate-release-solid-oral-dosage-forms. (accessed Dec. 22, 2020).
   Google Scholar
• European Medicines Agency. Guideline on the Investigation of Bioequivalence. https://www.ema.europa.eu/en/investigation-bioequivalence. (accessed Dec. 22, 2020).
   Google Scholar
• Romero, D. L.; Busso, M.; Tan, C. K.; Reusser, F.; Palmer, J. R.; Poppe, S. M.; Aristoff, P. A.; Downey, K. M.; So, A. G.; Resnick, L. Nonnucleoside Reverse Transcriptase Inhibitors That Potently and Specifically Block Human Immunodeficiency Virus Type 1 Replication. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 8806–8810. DOI: 10.1073/pnas.88.19.8806.
   PubMed Web of Science ®Google Scholar
• Spence, R. A.; Kati, W. M.; Anderson, K. S.; Johnson, K. A. Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors. Science 1995, 267, 988–993. DOI: 10.1126/science.7532321.
   PubMed Web of Science ®Google Scholar
• Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal Structure at 3.5 a Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor. Science 1992, 256, 1783–1790. DOI: 10.1126/science.1377403.
   PubMed Web of Science ®Google Scholar
• Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S. L-743, 726 (DMP-266): a Novel, Highly Potent Nonnucleoside Inhibitor of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 1995, 39, 2602–2605. DOI: 10.1128/AAC.39.12.2602.
   PubMed Web of Science ®Google Scholar
• Liu, P.; Foster, G.; LaBadie, R. R.; Gutierrez, M. J.; Sharma, A. Pharmacokinetic Interaction between Voriconazole and Efavirenz at Steady State in Healthy Male Subjects. J. Clin. Pharmacol. 2008, 48, 73–84. DOI: 10.1177/0091270007309703.
   PubMed Web of Science ®Google Scholar
• Veldkamp, A. I.; Harris, M.; Montaner, J. S. G.; Moyle, G.; Gazzard, B.; Youle, M.; Johnson, M.; Kwakkelstein, M. O.; Carlier, H.; van Leeuwen, R.; et al. The Steady-State Pharmacokinetics of Efavirenz and Nevirapine When Used in Combination in Human Immunodeficiency Virus Type 1-infected persons. J. Infect. Dis. 2001, 184, 37–42. DOI: 10.1086/320998.
   PubMed Web of Science ®Google Scholar
• Villani, P.; Regazzi, M. B.; Castelli, F.; Viale, P.; Torti, C.; Seminari, E.; Maserati, R. Pharmacokinetics of Efavirenz (EFV) Alone and in Combination Therapy with Nelfinavir (NFV) in HIV-1 Infected Patients. Br. J. Clin. Pharmacol. 1999, 48, 712–715. DOI: 10.1046/j.1365-2125.1999.00071.x.
   PubMed Web of Science ®Google Scholar
• Pfister, M.; Labbé, L.; Hammer, S. M.; Mellors, J.; Bennett, K. K.; Rosenkranz, S.; Sheiner, L. B. Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398. AAC. 2003, 47, 130–137. DOI: 10.1128/AAC.47.1.130-137.2003.
   Google Scholar
• Haas, D. W.; Ribaudo, H. J.; Kim, R. B.; Tierney, C.; Wilkinson, G. R.; Gulick, R. M.; Clifford, D. B.; Hulgan, T.; Marzolini, C.; Acosta, E. P. Pharmacogenetics of Efavirenz and Central Nervous System Side Effects: An Adult AIDS Clinical Trials Group Study. AIDS 2004, 18(18):2391–2400.
   Web of Science ®Google Scholar
• Günthard, H. F.; Saag, M. S.; Benson, C. A.; del Rio, C.; Eron, J. J.; Gallant, J. E.; Hoy, J. F.; Mugavero, M. J.; Sax, P. E.; Thompson, M. A.; et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016, 316, 191–210. DOI: 10.1001/jama.2016.8900.
   PubMed Web of Science ®Google Scholar
• Chiappetta, D. A.; Hocht, C.; Taira, C.; Sosnik, A. Oral Pharmacokinetics of the anti-HIV Efavirenz Encapsulated within Polymeric Micelles. Biomaterials 2011, 32, 2379–2387. DOI: 10.1016/j.biomaterials.2010.11.082.
   PubMed Web of Science ®Google Scholar
• http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines. (accessed December 22, 2020.
   Google Scholar
• Dogan-Topal, B.; Uslu, B.; Ozkan, S. A. Voltammetric Studies on the HIV-1 Inhibitory Drug Efavirenz: The Interaction between dsDNA and Drug Using Electrochemical DNA Biosensor and Adsorptive Stripping Voltammetric Determination on Disposable Pencil Graphite Electrode. Biosens. Bioelectron. 2009, 24, 2358–2364. DOI: 10.1016/j.bios.2008.12.005.
   PubMed Web of Science ®Google Scholar
• Castro, A. A.; Souza, MVN d.; Rey, N. A.; Farias, P. A. M. Determination of Efavirenz in Diluted Alkaline Electrolyte by Cathodic Adsorptive Stripping Voltammetry at the Mercury Film Electrode. J. Braz. Chem. Soc. 2011, 22, 1662–1668.
   Web of Science ®Google Scholar
• Thapliyal, N.; Osman, N. S. E.; Patel, H.; Karpoormath, R.; Goyal, R. N.; Moyo, T.; Patel, R. NiO–ZrO2 Nanocomposite Modified Electrode for the Sensitive and Selective Determination of Efavirenz, an anti-HIV Drug. RSC Adv. 2015, 5, 40057–40064. DOI: 10.1039/C5RA05286F.
   Web of Science ®Google Scholar
• Pourghobadi Zeinab, N. A. Electrochemical Behavior and Voltammetricdetermination of Efavirenz at Glassy Carbon Electrode Modified with Carbon Nanotubes. In Proceedings of the Iranian Biennial Electrochemistry Seminar; 2014.
   Google Scholar
• Raj, M.; Gupta, P.; Thapliyal, N.; Goyal, R. N. A Novel Hybrid Nano-Composite Grafted Electrochemically Reduced Graphene Oxide Based Sensor for Sensitive Determination of Efavirenz. Electroanalysis 2017, 29, 456–465. DOI: 10.1002/elan.201600397.
   Web of Science ®Google Scholar
• Görög, S. Identification in Drug Quality Control and Drug Research. TrAC Trends Anal. Chem. 2015, 69, 114–122. DOI: 10.1016/j.trac.2014.11.020.
   Web of Science ®Google Scholar
• Redasani, V. K.; Patel, P. R.; Marathe, D. Y.; Chaudhari, S. R.; Shirkhedkar, A. A.; Surana, S. J. A Review on Derivative uv-Spectrophotometry Analysis of Drugs in Pharmaceutical Formulations and Biological Samples Review. J. Chil. Chem. Soc. 2018, 63, 4126–4134. DOI: 10.4067/s0717-97072018000304126.
   Web of Science ®Google Scholar
• Deshpande, A.; Dhawale, S.; Gurav, S.; Walsangikar, S.; Gadgul, A.; Niranjane, K. Spectrophotometric Estimation of Efavirenz in Formulation and Biological Fluid. Int. J. Res. Pharm. Sci 2010, 1, 402–406.
   Google Scholar
• Tittikpina, N.; Wane, T.; Diouf, D.; Thiam, K.; Diop, A.; Fall, D.; Diop, Y.; Sarr, S. Development and Validation of a UV-Visible Method for the Determination of the Active Principle Efavirenz in Tablets. Int. J. Bio. Chem. Sci. 2020, 14, 279–288. DOI: 10.4314/ijbcs.v14i1.23.
   Google Scholar
• Nangare, A.; Pawa, K. S. A. Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry. Chemistry (Easton) 2014, 2, 134–144.
   Google Scholar
• Reddy, M. B. R. C.; Gillella, G. V. S. UV-Spectrophotometric Method for Estimation of Efavirenz in Bulk and Tablet Dosage Form. Int. J. Pharm. Sci. Res. 2012, 3, 5033.
   Google Scholar
• Rao, B. N.; Sunitha, N.; Teja, E. P.; Raju, G. S.; Babu, K. A.; Saibhaskar, K. V.; Pravallika, P. A.B. Method Development and Validation of Efavirenz by UV Spectrophotometer. IOSR J. Pharm. Biol. Sci. 2020, 15, 15–18. DOI: 10.9790/3008-1501021518.
   Google Scholar
• Slabiak, O.; Ivanchuk, I.; Tokaryk, G.; Klimenko, L.; Kolisnyk, I. Development and Validation of Uv-Spectrophotometric Procedures for Efavirenz Quantitative Determination. Int. J. Pharm. Qual. Assur. 2018, 9, 231–240. DOI: 10.25258/ijpqa.v9i3.13653.
   Google Scholar
• Kumar, Y. A.; Rao, N. R. Development of Rapid UV Spectrophotometric Method for the Estimation of Efavirenz in Formulations. E-J. Chem. 2010, 7, 434379. DOI: 10.1155/2010/434379.
   Google Scholar
• Siddiqui, M. R.; AlOthman, Z. A.; Rahman, N. Analytical Techniques in Pharmaceutical Analysis: A Review. Arab. J. Chem. 2017, 10, S1409–S1421. DOI: 10.1016/j.arabjc.2013.04.016.
   Web of Science ®Google Scholar
• Reddy, N.; Padmavathi, Y.; Mounika, P.; Anjali, A. FTIR Spectroscopy for Estimation of Efavirenz in Raw Material and Tablet Dosage Form. Int. Curr. Pharm. J. 2015, 4, 390–395. DOI: 10.3329/icpj.v4i6.23290.
   Google Scholar
• Shown, I.; Banerjee, S.; Ramchandran, A. V.; Geckeler, K. E.; Murthy, C. N. Synthesis of Cyclodextrin and Sugar-Based Oligomers for the Efavirenz Drug Delivery. Macromol. Symp. 2010, 287, 51–59. DOI: 10.1002/masy.201050108.
   Google Scholar
• Mgoyela, G.; Sempombe, J.; Kilulya, K.; Chambuso, M.; Mugoyela, V.; Kaale, E. A Quantitative near Infrared Spectroscopy Model for the Assay of Efavirenz in Tablets. East Cent. African J. Pharm. Sci. 2018, 17, 54–61.
   Google Scholar
• Bedor, D. C. G.; Souza Filho, J. H. d.; Ramos, V. L. S.; Gonçalves, T. M.; Sousa, C. E. M. d.; Santana, D. P. d. A Sensitive and Robust lc-ms/ms Method with Monolithic Column and Electrospray Ionization for the Quantitation of Efavirenz in Human Plasma: application to a Bioequivalence Study. Quím. Nova 2011, 34, 950–955. DOI: 10.1590/S0100-40422011000600007.
   Web of Science ®Google Scholar
• Jaishetty, N.; Palanisamy, K.; Maruthapillai, A.; Jaishetty, R. Trace Level Quantification of the (−)2-(2-Amino-5-Chlorophenyl)-4-Cyclopropyl-1,1,1-Trifluoro-3-Butyn-2-ol Genotoxic Impurity in Efavirenz Drug Substance and Drug Product Using LC–MS/MS. Sci. Pharm. 2016, 84, 456–466. DOI: 10.3390/scipharm84030456.
   Web of Science ®Google Scholar
• Kailasa, S. K.; Wu, H.-F. Rapid Quantification of Efavirenz in Human Plasma by Electrospray Ionization Tandem Mass Spectrometry. J. Chin.Chem. Soc. 2014, 61, 437–441. DOI: 10.1002/jccs.201300359.
   Web of Science ®Google Scholar
• de Aquino Ribeiro, J. A.; de Campos, L. M. M.; Alves, R. J.; Lages, G. P.; Pianetti, G. A. Efavirenz Related Compounds Preparation by Hydrolysis Procedure: Setting Reference Standards for Chromatographic Purity Analysis. J. Pharm. Biomed. Anal. 2007, 43, 298–303. DOI: 10.1016/j.jpba.2006.06.010.
   PubMed Web of Science ®Google Scholar
• Volosov, A.; Alexander, C.; Ting, L.; Soldin, S. J. Simple Rapid Method for Quantification of Antiretrovirals by Liquid Chromatography—Tandem Mass-Spectrometry. Clin. Biochem. 2002, 35, 99–103. DOI: 10.1016/S0009-9120(02)00286-2.
   PubMed Web of Science ®Google Scholar
• Rouzes, A.; Berthoin, K.; Xuereb, F.; Djabarouti, S.; Pellegrin, I.; Pellegrin, J. L.; Coupet, A. C.; Augagneur, S.; Budzinski, H.; Saux, M. C.; Breilh, D. Simultaneous Determination of the Antiretroviral Agents: amprenavir, Lopinavir, Ritonavir, Saquinavir and Efavirenz in Human Peripheral Blood Mononuclear Cells by high-performance liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 813, 209–216. DOI: 10.1016/j.jchromb.2004.09.041.
   PubMed Web of Science ®Google Scholar
• Johnston, J.; Orrell, C.; Smith, P.; Joubert, A.; Wiesner, L. A Validated Liquid Chromatography/Tandem Mass Spectrometry Method for the Analysis of Efavirenz in 0.2 mg Hair Samples from Human Immunodeficiency Virus Infected Patients. Rapid Commun. Mass Spectrom. 2018, 32, 657–664. DOI: 10.1002/rcm.8077.
   PubMedGoogle Scholar
• Sousa, EGR d.; Carvalho, E. M. d.; San Gil, R. A. d S.; Santos, T. C. D.; Borré, L. B.; Santos-Filho, O. A.; Ellena, J. Solution and Solid State Nuclear Magnetic Resonance Spectroscopic Characterization of Efavirenz. J. Pharm. Sci. 2016, 105, 2656–2664. DOI: 10.1016/j.xphs.2015.10.006.
   PubMed Web of Science ®Google Scholar
• Shamsipur, M.; Sarkouhi, M.; Hassan, J.; Haghgoo, S. Fluorine-19 Nuclear Magnetic Resonance (F-19 NMR) as a Powerful Technique for the Assay of anti-HIV Drug Efavirenz in Human Serum and Pharmaceutical Formulations. Afr. J. Pharm. Pharmacol. 2011, 5, 1573–1579. DOI: 10.5897/AJPP11.275.
   Google Scholar
• Sathigari, S.; Chadha, G.; Lee, Y.-H. P.; Wright, N.; Parsons, D. L.; Rangari, V. K.; Fasina, O.; Babu, R. J. Physicochemical Characterization of Efavirenz-cyclodextrin Inclusion Complexes. AAPS PharmSciTech. 2009, 10, 81–87. DOI: 10.1208/s12249-008-9180-3.
   PubMed Web of Science ®Google Scholar
• Sathigari, S.; Radhakrishnan, V.; Davis, V.; Parsons, D.; Babu, R. Amorphous-State Characterization of Efavirenz—Polymer Hot-Melt Extrusion Systems for Dissolution Enhancement. J. Pharm. Sci. 2012, 101, 3465–3464. DOI: 10.1002/jps.23125.
   PubMed Web of Science ®Google Scholar
• Taneja, S.; Shilpi, S.; Khatri, K. Formulation and Optimization of Efavirenz Nanosuspensions Using the Precipitation-Ultrasonication Technique for Solubility Enhancement. Artif. Cells. Nanomed. Biotechnol. 2016, 44, 978–984. DOI: 10.3109/21691401.2015.1008505.
   PubMed Web of Science ®Google Scholar
• Wardhana, Y. W.; Soewandhi, S. N.; Wikarsa, S.; Suendo, V. Polymorphic Properties and Dissolution Profile of Efavirenz Due to Solvents Recrystallization. Pak. J. Pharm. Sci. 2019, 32, 981–986.
   PubMed Web of Science ®Google Scholar
• Zaini, E.; Wahyu, D.; Octavia, M. D.; Fitriani, L. Influence of Milling Process on Efavirenz Solubility. J. Pharm. Bioall. Sci. 2017, 9, 22–25. DOI: 10.4103/0975-7406.206218.
   PubMed Web of Science ®Google Scholar
• Ramya, V.; Abbas, Z.; Swamy, N. G. N. Formulation and Evaluation of Efavirenz Compacts by Liquisolid Technique for Solubility Enhancement. Indian Drugs 2015, 52, 21–27.
   Google Scholar
• Chadha, R.; Arora, P.; Saini, A.; Singh Jain, D. An Insight into Thermodynamic Relationship between Polymorphic Forms of Efavirenz. J. Pharm. Pharm. Sci. 2012, 15, 234–251. DOI: 10.18433/J3J30Z.
   PubMed Web of Science ®Google Scholar
• Hamrapurkar, P.; Phale, M.; Shah, N. Quantitative Estimation of Efavirenz by High Performance Thin Layer Chromatography. J. Young Pharmacists 2009, 1, 359. DOI: 10.4103/0975-1483.59328.
   Google Scholar
• Tamilselvi, N.; Arivukkarasu, R.; Sasikala, R.; Shahanas, S.; Shamina, J. Development and Validation of HPTLC Method for the Determination of Efavirenz in Tablet Dosage Form. Res. J. Pharm. Tech. 2018, 11, 885–888. DOI: 10.5958/0974-360X.2018.00169.5.
   Google Scholar
• Nyamweru, B. C.; Kaale, E.; Mugoyela, V.; Chambuso, M. Development and Validation of an HPTLC-Densitometric Method for Simultaneous Analysis of Lamivudine, Tenofovir Disoproxil Fumarate, and Efavirenz (LTE) in Tablets. JPC-J. Planar Chromatogr.-Mod. TLC 2013, 26, 226–231. DOI: 10.1556/JPC.26.2013.3.4.
   Web of Science ®Google Scholar
• Rao, B.; Nikalje, A. Stability-Indicating HPLC Method for the Determination of Efavirenz in Bulk Drug and in Pharmaceutical Dosage Form. African J. Pharm. Pharmacol. 2009, 3, 643–650.
   Google Scholar
• Viana, O.; Medeiros, F.; Grangeiro-Júnior, S.; Albuquerque, M.; Soares, M.; Sobrinho, J.; Alves, L.; Rolim, L.; Silva, K.; Rolim-Neto, P. Development and Validation of a HPLC Analytical Assay Method for Efavirenz Tablets: A Medicine for HIV Infections. Brazilian J. Pharm. Sci. 2011, 47, 97–102. DOI: 10.1590/S1984-82502011000100012.
   Web of Science ®Google Scholar
• Gupta, S.; Kesarla, R.; Chotai, N.; Omri, A. Development and Validation of Reversed-Phase HPLC Gradient Method for the Estimation of Efavirenz in Plasma. PLoS One. 2017, 12, e0174777. DOI: 10.1371/journal.pone.0174777.
   PubMedGoogle Scholar
• Hoffman, J.; Rossi, S.; Espina-Quinto, R.; Letendre, S.; Capparelli, E. Determination of Efavirenz in Human Dried Blood Spots by Reversed-Phase high-performance liquid chromatography with UV detection. Ther. Drug Monit. 2013, 35, 203–208. DOI: 10.1097/FTD.0b013e31827fb72b.
   PubMed Web of Science ®Google Scholar
• Slabiak, O. I.; Ivanchuk, I. M.; Klimenko, L.; Tokaryk, G.; V; Lebedynets, V.; Yaremenko, V. D. Development and Validation of Hplc/uv-Procedure for Efavirenz Quantitative Determination. J. Pharm. Sci. Res. 2018, 10, 2829–2835.
   Google Scholar
• Langmann, P.; Schirmer, D.; Väth, T.; Zilly, M.; Klinker, H. High-Performance Liquid Chromatographic Method for the Determination of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz in Plasma of Patients during Highly Active Antiretroviral Therapy. J. Chromatogr. B Biomed. Sci. Appl. 2001, 755, 151–156. DOI: 10.1016/s0378-4347(01)00059-7.
   PubMed Web of Science ®Google Scholar
• Matthews, C. Z.; Woolf, E. J.; Mazenko, R. S.; Haddix-Wiener, H.; Chavez-Eng, C. M.; Constanzer, M. L.; Doss, G. A.; Matuszewski, B. K. Determination of Efavirenz, a Selective Non-Nucleoside Reverse Transcriptase Inhibitor, in Human Plasma Using HPLC with Post-Column Photochemical Derivatization and Fluorescence Detection. J. Pharm. Biomed. Anal. 2002, 28, 925–934. DOI: 10.1016/s0731-7085(01)00709-9.
   PubMed Web of Science ®Google Scholar
• Mogatle, S.; Kanfer, I. Rapid Method for the Quantitative Determination of Efavirenz in Human Plasma. J. Pharm. Biomed. Anal. 2009, 49, 1308–1312. DOI: 10.1016/j.jpba.2009.03.008.
   PubMed Web of Science ®Google Scholar
• Ramachandran, G.; Kumar, A. K. H.; Swaminathan, S.; Venkatesan, P.; Kumaraswami, V.; Greenblatt, D. J. Simple and Rapid Liquid Chromatography Method for Determination of Efavirenz in Plasma. J. Chromatog. B Analyt. Technol. Biomed. Life Sci. 2006, 835, 131–135. DOI: 10.1016/j.jchromb.2006.03.014.
   PubMed Web of Science ®Google Scholar
• Sarasa-Nacenta, M.; López-Púa, Y.; López-Cortés, L. F.; Mallolas, J.; Gatell, J. M.; Carné, X. Determination of Efavirenz in Human Plasma by High-Performance Liquid Chromatography with Ultraviolet Detection. J. Chromatogr. B Biomed. Sci. Appl. 2001, 763, 53–59. DOI: 10.1016/S0378-4347(01)00357-7.
   PubMed Web of Science ®Google Scholar
• Veldkamp, A. I.; van Heeswijk, R. P. G.; Meenhorst, P. L.; Mulder, J. W.; Lange, J. M. A.; Beijnen, J. H.; Hoetelmans, R. M. W. Quantitative Determination of Efavirenz (DMP 266), a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, in Human Plasma Using Isocratic Reversed-Phase High-Performance Liquid Chromatography with Ultraviolet Detection. J. Chromatogr. B Biomed. Sci. Appl. 1999, 734, 55–61. DOI: 10.1016/S0378-4347(99)00336-9.
   PubMedGoogle Scholar
• Deepakumari, H. N.; Mallegowda, S. M.; Prashanth, M. K.; Revanasiddappa, H. D. Bio Analytical Method Development of an anti-HIV-1 Drug Efavirenz Using High Performance Liquid Chromatography in Human Plasma. Mater. Today Proc. 2017, 4, 11939–11946. DOI: 10.1016/j.matpr.2017.09.115.
   Google Scholar
• Devrukhakar, P. S.; Borkar, R.; Shastri, N.; Surendranath, K. V. A Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Tenofovir, Emtricitabine, and a Efavirenz and Statistical Approach to Determine the Effect of Variables. ISRN Chromatogr 2013, 2013, 878295. DOI: 10.1155/2013/878295.
   Google Scholar
• Madhavi, B. B.; Kusum, B.; Chatanya, C. K.; Madhu, M. N.; Harsha, V. S.; Banji, D. Dissolution Enhancement of Efavirenz by Solid Dispersion and PEGylation Techniques. Int. J. Pharm. Investig. 2011, 1, 29–34. DOI: 10.4103/2230-973X.76726.
   PubMedGoogle Scholar
• Costa, M.; Seiceira, R.; Rodrigues, C.; Hoffmeister, C.; Cabral, L.; Rocha, H. Efavirenz Dissolution Enhancement I: Co-Micronization. Pharmaceutics 2012, 5, 1–22. DOI: 10.3390/pharmaceutics5010001.
   PubMedGoogle Scholar
• Jaydip, B.; Dhaval, M.; Soniwala, M. M.; Chavda, J. Formulation and Optimization of Liquisolid Compact for Enhancing Dissolution Properties of Efavirenz by Using DoE Approach. Saudi Pharm. J. 2020, 28, 737–745. DOI: 10.1016/j.jsps.2020.04.016.
   PubMed Web of Science ®Google Scholar
• Pinto, E.; do Carmo, F.; Honório, T.; Barros, R.; Castro, H.; Rodrigues, C.; Esteves, V.; Rocha, H.; Sousa, V.; Cabral, L. Influence of the Efavirenz Micronization on Tableting and Dissolution. Pharmaceutics 2012, 4, 430–441. DOI: 10.3390/pharmaceutics4030430.
   PubMedGoogle Scholar